TScan Therapeutics Announces Pause Of Enrollment In Phase 3 ALLOHA-2 Study Of TSC-101 Due To Insufficient Capital; Cuts Workforce About 75%, Extends Runway Into Q4 2027

Loading news article.

TScan Therapeutics Announces Pause Of Enrollment In Phase 3 ALLOHA-2 Study Of TSC-101 Due To Insufficient Capital; Cuts Workforce About 75%, Extends Runway Into Q4 2027 | WAPE

TScan Therapeutics Announces Pause Of Enrollment In Phase 3 ALLOHA-2 Study Of TSC-101 Due To Insufficient Capital; Cuts Workforce About 75%, Extends Runway Into Q4 2027

Article summary

Related companies

Comments —